• Suspended

NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Updated: May 23

NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma


PD-L1 Peptide Vaccination

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma


This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.


Sponsor:

Lene Meldgaard Knudsen


Collaborator:

IO Biotech


Locations

Denmark

 

ClinicalTrials.gov Identifier: NCT03850522


Official Title: Phase IIa Trial of PD-L1 Peptide Vaccination as Monotherapy in High Risk Smoldering Multiple Myeloma


First Posted : February 21, 2019


https://clinicaltrials.gov/ct2/show/NCT03850522

 

Biological: PD-L1 peptide

 

PD-L1 Peptide Vaccine


PD-L1 Peptide Vaccine (Code C148146)

PD-L1 Peptide

PD-L1 Peptide Vaccine




Posts Archive